NCT05415072 - A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2022

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2027

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG

DYP688

Single agent DYP688

Trial Locations (11)

Novartis Investigative Site, Westmead

Novartis Investigative Site, Leiden

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Zurich

Columbia University Medical Center- New York Presbyterian Onc Dept, New York

Memorial Sloane Kettering Cancer Center MSKCC, New York

Novartis Investigative Site, Madrid

Novartis Investigative Site, Essen

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Paris

Massachusetts General Hospital Hematology Oncology, Boston